

Access Clinically-relevant Gene Expression Algorithm Signatures for your Clinical Studies

A limited number of NanoString CRO partners are offering RUO gene signature reporting for biopharma clinical studies through NanoString's nAlgorithm™ Program

- ▶ RUO gene signature reporting includes:
- ▶ The tumor inflammation signature (TIS)
- ▶ DLBCL cell of origin subtyping (LST COO)
- ▶ PAM50 breast cancer signature
- ◆ Signatures can be reported from RUO IO 360, BC 360, LST and PAM50 assays (include branding for the assay circles for IO 360 and BC 360)
- ◆ TIS, LST and PAM50 signatures can be added to Custom and Panel Plus designs

Single Signatures	Description
Tumor Inflammation Signature (TIS)	Measures a pre-existing but suppressed adaptive immune response within tumors. TIS has been shown to enrich for patients who respond to the anti-PD1 agent pembrolizumab
Lymphoma Subtyping Test (LST)	Measures profile of cells found in diffuse large B-cell lymphoma (DLBCL) to classify Cell of Origin (COO)
PAM50	Measures intrinsic molecular subtypes which is prognostic in hormone-receptor positive postmenopausal breast cancer

CRO Global Partners offering nAlgorithm™



Want more information? Please fill out the below form to learn more:

[Learn More >](#)